Shabil Muhammed, Gaidhane Shilpa, Ballal Suhas, Kumar Sanjay, Bhat Mahakshit, Sharma Shilpa, Kumar M Ravi, Rustagi Sarvesh, Khatib Mahalaqua Nazli, Rai Nishant, Sah Sanjit, Mawejje Edward, Bushi Ganesh, Bhopte Kiran, Kathuria Rachna, Yappalparvi Ambanna
University Center for Research and Development, Chandigarh University, Mohali, Punjab, India.
Medical Laboratories Techniques Department, AL-Mustaqbal University, Hillah, Babil, 51001, Iraq.
Pneumonia (Nathan). 2024 Dec 25;16(1):30. doi: 10.1186/s41479-024-00149-5.
Pneumococcal disease, caused by Streptococcus pneumoniae, imposes a significant global health burden, particularly affecting vulnerable groups such as the elderly and immunocompromised. The 23-valent pneumococcal polysaccharide vaccine (PPV23) is designed to protect against 23 serotypes of Streptococcus pneumoniae. However, there is ongoing debate about its effectiveness in reducing all-cause mortality. This systematic review and meta-analysis aimed to evaluate the efficacy of PPV23 in reducing all-cause and pneumonia-related mortality among adults.
A systematic search was conducted across PubMed, Embase, and Web of Science, focusing on studies that evaluated the mortality outcomes of adults vaccinated with PPV23 compared to non-vaccinated adults. Both randomized controlled trials (RCTs) and observational studies were included, while case reports, case series, and non-human studies were excluded. Data extraction and quality assessment were facilitated by Nested Knowledge software, using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for RCTs.
The search yielded 826 records, with 19 studies meeting the inclusion criteria. The pooled analysis of four RCTs showed no significant reduction in all-cause mortality (RR = 1.030; 95% CI: 0.945, 1.122). However, analysis of pneumonia-related mortality across various studies indicated a significant reduction (HR = 0.504; 95% CI: 0.316, 0.693). Moderate to high heterogeneity was noted in mortality studies, and a potential publication bias was identified.
The findings suggest that while PPV23 may not significantly reduce all-cause mortality, it is effective in reducing pneumonia-related mortality among adults, particularly in those at higher risk. These results support the continued use of PPV23 in targeted adult populations, emphasizing the need for more primary studies to explore its effectiveness across diverse groups.
由肺炎链球菌引起的肺炎球菌疾病给全球健康带来了重大负担,尤其影响老年人和免疫功能低下等弱势群体。23价肺炎球菌多糖疫苗(PPV23)旨在预防23种肺炎链球菌血清型。然而,关于其在降低全因死亡率方面的有效性仍存在争议。本系统评价和荟萃分析旨在评估PPV23在降低成人全因死亡率和肺炎相关死亡率方面的疗效。
在PubMed、Embase和科学网进行了系统检索,重点关注评估接种PPV23的成人与未接种成人死亡率结果的研究。纳入了随机对照试验(RCT)和观察性研究,排除了病例报告、病例系列和非人类研究。使用Nested Knowledge软件进行数据提取和质量评估,观察性研究采用纽卡斯尔-渥太华量表,RCT采用Cochrane偏倚风险工具。
检索共获得826条记录,19项研究符合纳入标准。四项RCT的汇总分析显示全因死亡率无显著降低(RR = 1.030;95% CI:0.945,1.122)。然而,对各项研究中肺炎相关死亡率的分析表明有显著降低(HR = 0.504;95% CI:0.316,0.693)。在死亡率研究中发现了中度到高度的异质性,并识别出潜在的发表偏倚。
研究结果表明,虽然PPV23可能不会显著降低全因死亡率,但它在降低成人肺炎相关死亡率方面是有效的,尤其是在高危人群中。这些结果支持在目标成人人群中继续使用PPV23,强调需要更多的基础研究来探索其在不同人群中的有效性。